ABSTRACT
In August of 1989, the FDA made it clear to members of the generic drug industry thatmany aspects of cGMPs apply to the product development process. The unfortunate problems uncovered at that time led Agency Investigators to request, for the ¢rst time, records showing how formulations were developed. Disappointingly, many ¢rms had little documentation related to product development activities.
